免疫组化检测的细胞内幽门螺杆菌:根除失败的缺失环节
该研究分析814例初治幽门螺杆菌感染患者胃活检标本,用免疫组化检测表观细胞内幽门螺杆菌(aiHp)。aiHp见于61%患者,且是含克拉霉素三联疗法根除失败的独立预测因素;在克拉霉素敏感菌株中,aiHp病例根除率仍低于无aiHp者。
要点
- aiHp多见于胃体活检且菌量低,胃窦活检少见。
- aiHp是初治含克拉霉素三联疗法根除失败的独立危险因素。
- 克拉霉素敏感菌株中,aiHp者根除率仍低于无aiHp者。
核心结论
- 免疫组化检测到的aiHp尤其是胃体活检中的aiHp是初治三联疗法根除失败的危险因素。
- aiHp的存在应在选择治疗方案时加以考虑。
研究设计与样本
- 对814例初治幽门螺杆菌感染患者的胃活检标本在根除治疗前后进行免疫组化分析。
- 其中373例接受阿莫西林、克拉霉素和质子泵抑制剂(AC/PPI)治疗。
- 在AC/PPI组内按治疗前胃活检的克拉霉素药敏PCR结果匹配52例aiHp与52例非aiHp病例。
主要发现
- aiHp主要见于胃体活检且菌量低,胃窦活检少见(95.2% vs 24.6%)。
- 全部患者中497例(61%)检出aiHp,AC/PPI组373例中192例(51.5%)检出。
- 全样本中aiHp与非aiHp病例根除率分别为44.4%与72.9%,AC/PPI组分别为45.3%与66.8%。
- 104例匹配患者中根除率分别为46.2%与78.8%;克拉霉素敏感病例中分别为60.6%与91.9%。
临床怎么用
- 对初治幽门螺杆菌感染患者,尤其是胃体活检检出aiHp者,应警惕含克拉霉素三联疗法根除失败风险。
- aiHp的存在可作为选择治疗方案时的参考因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Helicobacter pylori is primarily an extracellularly living bacterium. However, seemingly intracellular occurrence can often be detected by immunohistochemical stains. Considering antimicrobial resistance, we investigated the impact of the apparent intracellular H. pylori (aiHp) on treatment failure of first-line triple therapies. METHODS: Gastric biopsies of 814 patients infected with H. pylori naive to treatment were analyzed before and after eradication therapy by immunohistochemistry. Of these, 373 received treatment consisting of amoxicillin, clarithromycin, and proton pump inhibitor (AC/PPI). Availability of polymerase chain reaction-based clarithromycin susceptibility test results from pretreatment gastric biopsies was a precondition for matching 52 aiHp to 52 non-aiHp cases within the AC/PPI group. RESULTS: AiHp were detected mostly in low counts predominantly in corpus biopsies, rarely in antrum biopsies (95.2% vs 24.6%); they were found in 497 (61%) of all patients and in 192 of 373 patients (51.5%) in the AC/PPI group. The eradication rate in aiHp versus non-aiHp cases was 44.4% versus 72.9% in the entire sample and 45.3% versus 66.8% in the AC/PPI group. Among the 104 paired patients, respective values were 46.2% versus 78.8%; in clarithromycin-susceptible cases, 60.6% versus 91.9%. Both aiHp and resistance to clarithromycin proved to be highly significant (P ≤ .001) and independent predictors of eradication failure. Twelve of 13 aiHp cases with a clarithromycin-sensitive strain who failed eradication developed resistance to the antibiotic. CONCLUSIONS: AiHp found by immunohistochemical staining especially in corpus biopsies proved to be a risk factor for failure of first-line triple therapies; occurrence of aiHp should be considered with regard to therapy options.
引用
- Beer A, Hudler H, Hader M, et al. Apparent Intracellular Helicobacter pylori Detected by Immunohistochemistry: The Missing Link in Eradication Failure. Clin Infect Dis. 2021. PMID: 32569354. doi:10.1093/cid/ciaa839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。